Company intelligence / Profile preview

VedTechBio

Bengaluru, Karnataka, Indiavedtechbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

VedTechBio leverages its RxAgentAI platform to accelerate drug discovery for clients, including target identification, hit finding, compound design, and preclinical validation. The company has demonstrated success in identifying protein targets, designing hit compounds from large libraries, advancing them to synthesis and proof-of-concept stages. It collaborates with biopharma partners on both novel target identification and repurposing strategies but does not disclose proprietary clinical results or late-stage programs.

Modalities: Small moleculeAI-driven drug design (enabling technology, not a therapeutic modality)
Industry: Drug Discovery Services

Partnerships

RenaissThera (drug discovery collaboration for metabolic disease therapies using RxAgentAI)AlphaMeld Corporation (strategic AI partnership)

Beyond the preview

Go deeper on VedTechBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VedTechBio.

Explore the full profile